ATC Group: C09CA07 Telmisartan

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C09CA07 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C09 Agents acting on the renin-angiotensin system
3 C09C Angiotensin II antagonists, plain
4 C09CA Angiotensin II antagonists, plain
5 C09CA07 Telmisartan

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 40 mg

Active ingredients in C09CA07

Active Ingredient Description
Telmisartan

Telmisartan is an orally active and specific angiotensin II receptor (type AT1) antagonist. Telmisartan selectively binds the AT1 receptor. The binding is long-lasting.

Related product monographs

Title Information Source Document Type  
MICARDIS Tablet European Medicines Agency (EU) MPI, EU: SmPC
MIZART Tablet Pharmaceutical Benefits Scheme (AU) MPI, EU: SmPC
TELTARTAN Tablet Pharmaceutical Benefits Scheme (AU) MPI, EU: SmPC
TOLURA Tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Brazil (BR)

Canada (CA)

Cyprus (CY)

Finland (FI)

France (FR)

Germany (DE)

Italy (IT)

Japan (JP)

Mexico (MX)

Netherlands (NL)

Romania (RO)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.